[1] FanJ G, Li X Y. NAFLD renaming to MAFLD, MASLD: background, similarities, differences, and countermeasures[J]. Chin J Hepatol, 2023, 31(8): 789-792.
[2] RianikP, De L L, Dolinsek J, et al. Clinical presentation in children with coeliac disease in central Europe[J]. J Pediatr Gastroenterol Nutr, 2021, 72(4): 546-551.
[3] Al-tomaA, Volta U, Auricchio R, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders[J]. UEG Journal, 2019, 7(5): 583-613.
[4] Rubio-tapiaA, Murray J A. The liver and celiac disease[J]. Clin Liver Dis, 2019, 23(2): 167-176.
[5] YounossiZ, Anstee Q M, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention[J]. Nat Rev Gastro Hepat, 2018, 15(1): 11-20.
[6] ZengJ, Jin Q, Yang J, et al. Prevalence and incidence of MAFLD and associated anthropometric parameters among prepubertal children of the Shanghai Birth Cohort[J]. Hepatol Int, 2023, 17(6): 1-13.
[7] AltayD, Doğan Y. Liver involvement in children during the diagnosis of celiac disease: a single-center experience from Turkey[J]. Middle East J Dig Dis, 2022, 14(2): 200-206.
[8] YodoshiT, Orkin S, Arce-clachar A C, et al. Alternative etiologies of liver disease in children with suspected NAFLD[J]. Pediatrics, 2021, 147(4):e2020009829.
[9] ValvanoM,Longo S,Stefanelli G,et al. Celiac disease,gluten-free diet,and metabolic and liver disorders[J].Nutrients,2020,12(4):940.
[10] TovoliF, Negrini G, Farì R,et al. Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free diet: beyond traditional metabolic factors[J]. Aliment Pharmacol Ther. 2018, 48(5), 538-546.
[11] BjørndalB, Alterås E K, Lindquist C, et al. Associations between fatty acid oxidation, hepatic mitochondrial function, and plasma acylcarnitine levels in mice[J]. Nutr Metab (Lond), 2018, 15: 10.
[12] MedzaA, Szlagatys-sidorkiewicz A. Nutritional status and metabolism in celiac disease: narrative review[J]. J Clin Med, 2023, 12(15): 5107.
[13] JabeenS, Khan A U, Ahmed W, et al. Disease specific symptoms indices in patients with celiac disease—A hardly recognised entity[J]. Front. Nutr, 2022, 9: 944449.
[14] FuC C, Zhang X Y, Xu L, et al. PPARγ dysfunction in the medial prefrontal cortex mediates high-fat diet-induced depression[J]. Mol. Neurobiol, 2022, 59(7): 4030-4043.
[15] Unalp-aridaA, Ruhl C E, Choung R S, et al. Lower prevalence of celiac disease and gluten-related disorders in persons living in southern vs northern latitudes of the United States[J]. Gastroenterology, 2017, 152(8): 1922-1932.
[16] DeRe V, Magris R, Cannizzaro R. New insights into the pathogenesis of celiac disease[J]. Front Med (Lausanne), 2017, 4: 137.
[17] VerduE F, Schuppan D. Co-factors, microbes, and immunogenetics in celiac disease to guide novel approaches for diagnosis and treatment[J]. Gastroenterology, 2021, 161(5): 1395-1411.
[18] KallaR, Adams A T, Nowak J K, et al. Analysis of systemic epigenetic alterations in inflammatory bowel disease: defining geographical, genetic and immune-inflammatory influences on the circulating methylome[J]. J Crohns Colitis, 2023, 17(2): 170-184.
[19] StasinouE, Emmanouilidou-fotoulaki E, Kavga M, et al. Association of rs738409 polymorphism in adiponutrin gene with liver steatosis and atherosclerosis risk factors in greek children and adolescents[J]. Nutrients, 2022, 14(17): 3452.
[20] AlbillosA, De Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy[J]. J. Hepatol, 2020, 72(3): 558-577.
[21] HeydariK, Yousefi M, Alizadeh-navaei R, et al. Helicobacter pylori infection and non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. Turk J Gastroenterol, 2022,33(3):171-181.
[22] DydensborgSander S, Nybo Andersen A M, Murray J A, et al. Association between antibiotics in the first year of life and celiac disease[J]. Gastroenterology, 2019,156(8):2217-2229.
[23] MillsS, Yang B, Smith G J, et al. Efficacy of Bifidobacterium longum alone or in multi-strain probiotic formulations during early life and beyond[J]. Gut Microbes, 2023, 15(1): 2186098.
[24] WoodhouseC A, Patel V C, Singanayagam A, et al. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease[J]. Aliment Pharm Ther, 2018, 47(2): 192-202.
[25] Yangm,Li F, Zhang R, et al. Alteration of the intestinal microbial flora and the serum IL-17 level in patients with Graves' disease complicated with vitamin D deficiency[J]. Int Arch Allergy Imm, 2022, 183(2): 225-234.
[26] GasalyN, De Vos P, Hermoso M A. Impact of bacterial metabolites on gut barrier function and host immunity: a focus on bacterial metabolism and its relevance for intestinal inflammation[J]. Front Immunol, 2021, 12: 658354.
[27] Martin-gallausiauxC, Marinelli L, Blottière H M, et al. SCFA: mechanisms and functional importance in the gut[J]. Proc Nutr Soc, 2021, 80(1): 37-49.
[28] Narciso-schiavonJ L, Schiavon L L. Fatty liver and celiac disease: why worry?[J]. World J Hepatol, 2023,15(5):666-674.
[29] MarraF, Svegliati-baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis[J]. J Hepatol,2018,68(2):280-295.
[30] JiJ, Wu L, Wei J, et al. The gut microbiome and ferroptosis in MAFLD[J]. J Clin Transl Hepatol,2023,11(1):174-187.
[31] ArabJ P, Arrese M, Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease[J]. Annu Rev Pathol, 2018, 13: 321-350.
[32] NassirF. NAFLD: mechanisms, treatments, and biomarkers[J]. Biomolecules, 2022, 12(6):824.
[33] GarciaN M, Cohen N A, Rubin D T. Treat-to-target and sequencing therapies in Crohn′s disease[J]. United European Gastroenterol J, 2022, 10(10): 1121-1128.
[34] SerenaG, Fasano A. Use of probiotics to prevent celiac disease and IBD in pediatrics[J]. Adv Exp Med Biol, 2019, 1125: 69-81.
[35] HusbyS, Bai J C. Follow-up of celiac disease[J]. Gastroenterol Clin N, 2019, 48(1): 127-136. |
